Kymera Therapeutics Reports Shareholder Vote Matters

Ticker: KYMR · Form: 8-K · Filed: Jun 27, 2025 · CIK: 1815442

Kymera Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyKymera Therapeutics, Inc. (KYMR)
Form Type8-K
Filed DateJun 27, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: KYMR

TL;DR

Kymera shareholders voted on important company matters on June 25th.

AI Summary

Kymera Therapeutics, Inc. filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders on June 25, 2025. The filing details the company's corporate actions and decisions put before its shareholders for approval.

Why It Matters

This filing indicates key corporate governance decisions were made, which could impact the company's strategic direction and shareholder rights.

Risk Assessment

Risk Level: low — This is a routine corporate filing detailing shareholder votes, not indicating new financial risks or operational changes.

Key Players & Entities

  • Kymera Therapeutics, Inc. (company) — Registrant
  • June 27, 2025 (date) — Filing Date
  • June 25, 2025 (date) — Date of Earliest Event Reported

FAQ

What specific matters were submitted to a vote of Kymera Therapeutics' security holders?

The filing states that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

When did the earliest event reported in this 8-K filing occur?

The earliest event reported occurred on June 25, 2025.

What is the filing date of this 8-K report?

The filing date of this 8-K report is June 27, 2025.

What is the principal executive office address for Kymera Therapeutics, Inc.?

The principal executive offices are located at 500 North Beacon Street, 4th Floor, Watertown, Massachusetts 02472.

What is Kymera Therapeutics' telephone number?

Kymera Therapeutics' telephone number is (857) 285-5300.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding Kymera Therapeutics, Inc. (KYMR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.